Barclays
CADL icon

Barclays’s Candel Therapeutics CADL Stock Holding History

Barclays’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.3K Sell
11,699
-57,645
-83% -$314K ﹤0.01% 4266
2025
Q4 		$392K Buy
69,344
+9,749
+16% +$52.4K ﹤0.01% 3983
2025
Q3 		$304K Sell
59,595
-8,841
-13% -$51.1K ﹤0.01% 4089
2025
Q2 		$346K Buy
68,436
+37,114
+118% +$191K ﹤0.01% 3969
2025
Q1 		$177K Sell
31,322
-2,995
-9% -$24.5K ﹤0.01% 4124
2024
Q4 		$298K Buy
34,317
+5,629
+20% +$33.3K ﹤0.01% 4125
2024
Q3 		$199K Buy
28,688
+21,971
+327% +$136K ﹤0.01% 4293
2024
Q2 		$41.6K Buy
+6,717
New +$50.4K ﹤0.01% 4277

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's CADL Position: Q1 2026 in Review

Barclays reduced its Candel Therapeutics (CADL) stake by 83% in Q1 2026, selling an estimated $314K and leaving 11,699 shares worth $57.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4266.

Barclays first reported a position in CADL in Q2 2024 and has held it in 8 quarters since. The position peaked at $392K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Barclays held 11,699 shares of Candel Therapeutics worth $57.3K as of Q1 2026.
  • Barclays sold 57,645 Candel Therapeutics shares in Q1 2026, an estimated $314K.
  • Candel Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4266 holding.
  • Barclays first reported a position in Candel Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Barclays's Candel Therapeutics position peaked at $392K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.